GlycoMimetics (GLYC) Scheduled to Post Earnings on Thursday

GlycoMimetics (NASDAQ:GLYC) is scheduled to be releasing its earnings data before the market opens on Thursday, May 9th. Analysts expect GlycoMimetics to post earnings of ($0.15) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings results on Wednesday, March 27th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. The company had revenue of $0.01 million during the quarter. On average, analysts expect GlycoMimetics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GlycoMimetics Stock Down 10.0 %

NASDAQ:GLYC opened at $1.62 on Thursday. GlycoMimetics has a twelve month low of $1.11 and a twelve month high of $3.53. The firm has a market capitalization of $104.41 million, a price-to-earnings ratio of -2.79 and a beta of 2.18. The stock’s 50 day moving average price is $2.58 and its two-hundred day moving average price is $2.33.

Wall Street Analyst Weigh In

GLYC has been the topic of a number of recent analyst reports. StockNews.com downgraded shares of GlycoMimetics from a “hold” rating to a “sell” rating in a report on Thursday, March 14th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of GlycoMimetics in a report on Wednesday, March 27th. Finally, Capital One Financial reiterated an “overweight” rating on shares of GlycoMimetics in a research note on Thursday, February 22nd.

About GlycoMimetics

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.